Becton Dickinson
BDX
$142.35
-0.78%
Becton, Dickinson and Co. (BD) is a global medical technology company operating in the Healthcare sector, specifically within Medical Instruments & Supplies. It is the world's largest manufacturer and distributor of essential medical surgical products like needles and syringes, and also produces diagnostic instruments, reagents, and cell-imaging systems. The company is a dominant market leader with a diversified portfolio across four segments: Medical Essentials, Interventional, Connected Care, and Biopharma. The current investor narrative is dominated by a significant stock price decline following its Q2 2026 earnings report, despite the company delivering a strong beat and raising its full-year profit outlook, indicating a stark disconnect between operational performance and market sentiment that is driving intense debate.…
BDX
Becton Dickinson
$142.35
Related headlines
Investment Opinion: Should I buy BDX Today?
Rating & Thesis: Hold. BDX presents a classic 'value trap' scenario—deeply undervalued on a forward earnings basis but facing legitimate fundamental headwinds that justify market skepticism. The core thesis is that the stock is fairly valued at current levels, balancing a low 10.67x forward P/E against decelerating growth and margin pressure, with analyst sentiment mixed between Buy and Neutral.
Supporting Evidence: The primary valuation metric, the forward P/E of 10.67x, represents a steep 58% discount to the trailing P/E of 25.13x, pricing in significant earnings growth. However, Q1 revenue growth of 1.63% YoY shows deceleration, and profitability is weakening with gross margin down to 44.63%. Positively, the company generates robust annual FCF of $2.63B to support its operations and 2.8% dividend yield. The stock trades at a historical valuation low relative to its own past multiples, which frequently exceeded 30x.
Risks & Conditions: The two biggest risks are 1) revenue growth failing to re-accelerate, and 2) further gross margin compression eroding the path to promised profits. This Hold rating would upgrade to a Buy if the company demonstrates a clear reversal in Q2, with revenue growth re-accelerating above 5% YoY and gross margins stabilizing above 46%. It would downgrade to a Sell if revenue growth turns negative or if the stock breaks below the $127.59 support level on sustained negative momentum. The stock is fairly valued relative to its immediate challenges but undervalued relative to its long-term cash-generating potential.
Sign up to view all
BDX 12-Month Price Forecast
BDX is at an inflection point. The valuation is compelling, but the fundamentals are sending warning signals. The base case of a grinding, range-bound recovery is most probable, as the company's strong cash flow and market position provide a floor, while growth and margin challenges cap the upside. The AI stance is Neutral with Medium confidence. Confidence would increase to High on a Bullish stance if the next quarterly report shows a clear reversal in revenue growth trajectory and margin stabilization. Conversely, evidence of further deterioration in either metric would shift the stance to Bearish.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Becton Dickinson's 12-month outlook, with a consensus price target around $185.06 and implied upside of +30.0% versus the current price.
Average Target
$185.06
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$114 - $185
Analyst target range
Analyst coverage for BDX appears limited in the provided dataset, with only 4 analysts cited for estimates, suggesting institutional coverage may be more extensive but data is incomplete. The consensus sentiment, inferred from recent institutional ratings, leans cautiously positive with firms like Argus Research, Citigroup, Jefferies, and Stifel maintaining 'Buy' ratings, while others like JP Morgan, Wells Fargo, Piper Sandler, and RBC Capital maintain 'Neutral' or 'Sector Perform' equivalents. The target price range is not explicitly provided in the data, but the wide dispersion in analyst actions following the Q2 report—where the company raised guidance yet the stock sold off—signals high uncertainty and a lack of conviction, with the low targets likely pricing in continued margin pressure and growth concerns, while high targets would assume successful execution on the raised profit outlook and a re-rating.
Bulls vs Bears: BDX Investment Factors
The evidence currently tilts bearish, driven by the severe technical breakdown, decelerating growth, and margin compression that have overwhelmed the stock's attractive valuation and strong cash flow. The most critical tension in the investment debate is whether the company's raised profit outlook and low forward P/E (10.67x) accurately forecast a successful operational turnaround, or if the deteriorating revenue growth (1.63% YoY) and margins signal deeper fundamental issues that will prevent earnings from meeting elevated expectations. The resolution of this growth-versus-profitability squeeze will determine the stock's direction.
Bullish
- Deep Valuation Discount: BDX's forward P/E of 10.67x is a significant discount to its trailing P/E of 25.13x, implying the market expects a substantial earnings recovery. This forward multiple is also below the stock's own historical trading range, which has frequently been above 30x, suggesting a potential value opportunity if earnings stabilize as guided.
- Strong Free Cash Flow Generation: The company generates robust annual free cash flow of $2.63 billion (TTM), providing ample internal funding for its 2.8% dividend yield, share buybacks, and strategic investments. This financial strength supports the balance sheet, evidenced by a manageable debt-to-equity ratio of 0.76.
- Raised Profit Outlook: Despite the stock's sell-off, the company recently delivered a strong Q2 FY2026 earnings beat and raised its full-year profit outlook. This operational strength signals management confidence in overcoming near-term margin pressures and executing on its strategic plan.
- Dominant Market Position: As the world's largest manufacturer of essential medical surgical products, BDX holds a leading, diversified portfolio across four segments. This entrenched market position in non-discretionary healthcare provides a defensive revenue base, with 43% of sales coming from international markets.
Bearish
- Severe Price and Momentum Downtrend: The stock is in a pronounced downtrend, down 25.68% over six months and 18.43% over three months, severely underperforming the S&P 500 by -26.85 points. Trading at $143.47, it is near the bottom of its 52-week range, indicating persistent negative sentiment and potential for further technical breakdown.
- Decelerating Revenue Growth: Q1 FY2026 revenue growth decelerated sharply to 1.63% YoY from 8.3% in Q4 FY2025 and 10.4% in Q3 FY2025. This slowdown in the top-line trajectory raises concerns about the company's growth profile and its ability to meet future earnings expectations embedded in the low forward P/E.
- Compressing Profitability Margins: Key profitability metrics are under pressure. The Q1 gross margin compressed to 44.63% from 47.50% in the prior quarter, and the net margin fell to 7.27% from 8.37%. This margin erosion, if sustained, threatens the earnings recovery anticipated by the forward valuation.
- Analyst Skepticism Despite Guidance: The market's reaction to the raised profit outlook—a significant stock sell-off—highlights a stark disconnect and deep analyst skepticism. The limited number of analysts (4) providing estimates and the mix of 'Buy' and 'Neutral' ratings suggest a lack of conviction and high uncertainty around the company's near-term path.
BDX Technical Analysis
The stock is in a pronounced and sustained downtrend, having declined 16.72% over the past year and a severe 25.68% over the last six months. As of the latest close at $143.47, the price is trading near the bottom of its 52-week range, at approximately 76.6% of the distance from its 52-week high of $187.35 to its low of $127.59, positioning it as a potential value opportunity but also signaling significant negative momentum that could indicate further fundamental concerns. Recent momentum is decisively negative and accelerating the longer-term downtrend, with the stock down 7.75% over the past month and 18.43% over the past three months, starkly underperforming the S&P 500 which gained 5.6% and 8.42% over the same periods, respectively, as evidenced by the severe relative strength readings of -13.35 and -26.85. Key technical support is clearly defined at the 52-week low of $127.59, while resistance sits at the recent breakdown level near the 52-week high of $187.35; a breakdown below $127.59 would signal a new phase of weakness, while any recovery would first need to reclaim the $170-$180 zone. The stock's beta of 0.285 indicates it is significantly less volatile than the broader market, which ironically has not protected it from a deep drawdown of -31.84%, suggesting company-specific issues are the primary driver.
Beta
0.28
0.28x market volatility
Max Drawdown
-32.2%
Largest decline past year
52-Week Range
$128-$187
Price range past year
Annual Return
-18.8%
Cumulative gain past year
| Period | BDX Return | S&P 500 |
|---|---|---|
| 1m | -10.2% | +4.0% |
| 3m | -19.7% | +8.2% |
| 6m | -25.6% | +11.5% |
| 1y | -18.8% | +24.3% |
| ytd | -27.0% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BDX Fundamental Analysis
Revenue growth is modest but positive, with Q1 FY2026 revenue of $5.25 billion representing a 1.63% year-over-year increase; however, this marks a deceleration from the stronger growth seen in prior quarters like Q4 FY2025 (8.3% YoY on $5.89B) and Q3 FY2025 (10.4% YoY on $5.51B), indicating a potential slowdown in the top-line trajectory. The company remains profitable with a Q1 net income of $382 million, but profitability metrics show pressure as the net margin of 7.27% in Q1 is down from 8.37% in Q4, and the gross margin of 44.63% has compressed from 47.50% the prior quarter, reflecting potential cost inflation or mix shifts. Balance sheet and cash flow health is solid, with a manageable debt-to-equity ratio of 0.76, a current ratio of 1.11 indicating adequate short-term liquidity, and robust annual free cash flow generation of $2.63 billion (TTM) providing ample internal funding for dividends, buybacks, and growth investments.
Quarterly Revenue
$5.3B
2025-12
Revenue YoY Growth
+0.01%
YoY Comparison
Gross Margin
+0.44%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BDX Overvalued?
Given the company's consistent profitability with positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE stands at 25.13x, while the forward PE is significantly lower at 10.67x, indicating the market expects a substantial recovery in earnings over the next twelve months. Compared to sector averages, BDX's trailing PE of 25.13x trades at a premium; for context, its Price-to-Sales ratio of 1.93x and EV/EBITDA of 12.21x provide additional valuation anchors, but the forward PE discount suggests the market has already priced in significant near-term earnings growth or multiple compression. Historically, the current trailing PE of 25.13x is below the stock's own historical range seen over the past several years, where it has frequently traded above 30x, suggesting the stock is at a relative valuation low within its own history, which could indicate a value opportunity if fundamentals stabilize.
PE
25.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 13x~107x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is the sharp deceleration in revenue growth to 1.63% YoY in Q1 FY2026, which calls into question the sustainability of earnings needed to justify the forward P/E of 10.67x. Concurrently, profitability is under pressure, with gross margin compressing 287 basis points sequentially to 44.63% and net margin falling to 7.27%. While the balance sheet is solid with a debt-to-equity of 0.76 and strong $2.63B annual FCF, the company depends on reversing these negative trends to validate its guidance and prevent further multiple compression.
Market & Competitive Risks: BDX faces significant valuation compression risk. Its trailing P/E of 25.13x trades at a premium to the sector, yet the stock has already fallen 31.84% from its high. The low beta of 0.285 failed to provide downside protection, indicating company-specific issues are the primary driver. Competitive and regulatory pressures in the medical supplies sector could further pressure pricing and margins. The stock's severe underperformance (-26.85 points vs. SPY over 3 months) also exposes it to sector rotation away from perceived value traps within healthcare.
Worst-Case Scenario: The worst-case scenario involves a continuation of the current trends: revenue growth stagnates near 1-2%, margin compression persists due to cost inflation and competitive pressures, and the company fails to deliver on its raised profit outlook. This would lead to multiple analyst downgrades and a re-rating to a deeper discount. The stock could realistically test and break its 52-week low of $127.59, representing a further downside of approximately -11% from the current price of $143.47. A drawn-out downturn could see the stock fall toward the $120-$125 range, a total peak-to-trough drawdown exceeding -35%.
FAQ
The key risks are, in order of severity: 1) Growth Stagnation Risk: Revenue growth decelerated sharply to 1.63% YoY; if this persists, earnings will disappoint. 2) Margin Compression Risk: Q1 gross margin fell to 44.63% from 47.50%; further erosion would directly hit profitability. 3) Technical Breakdown Risk: The stock is in a severe downtrend and a break below the $127.59 support could trigger accelerated selling. 4) Sentiment & Valuation Risk: Despite raising guidance, the stock sold off, indicating deep-seated skepticism that could keep the multiple depressed even if results improve.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $145-$165 as the company meets its profit guidance but growth remains muted, justifying the current ~10.7x forward P/E. The Bull Case (25% probability) targets $187-$205 on successful execution, margin recovery, and a valuation re-rating. The Bear Case (15% probability) risks a fall to the $127-$140 range if growth stalls and margins weaken further. The Base Case is most likely, hinging on the assumption that revenue growth stabilizes, even at low levels, and does not deteriorate further.
BDX appears undervalued on a forward earnings basis but fairly valued when considering its growth challenges. The forward P/E of 10.67x is a deep discount to its own historical average (often >30x) and suggests the market expects a strong earnings recovery. However, the trailing P/E of 25.13x is at a premium to the sector, and the weak revenue growth justifies skepticism. The valuation implies the market is paying a fair price for a company in transition, with a significant discount applied for execution risk. It is not egregiously overvalued, but the undervaluation is conditional on a business recovery.
BDX is a speculative buy for patient, value-oriented investors, but not a clear-cut good buy for all. The forward P/E of 10.67x is very attractive and prices in significant pessimism, offering a 2.8% dividend yield supported by strong cash flow. However, the severe price downtrend (-25.7% over 6 months) and decelerating 1.63% revenue growth present substantial near-term risk. It could be a good buy for those betting on a successful turnaround and willing to endure volatility, but investors seeking stability or growth should wait for clearer signs of fundamental improvement.
BDX is primarily suitable for a long-term investment horizon of 3-5 years, not short-term trading. Its low beta of 0.285 indicates low correlation to daily market swings, making it a poor trading vehicle. The investment thesis is based on a eventual turnaround and valuation mean reversion, which requires time to unfold. The 2.8% dividend provides income while waiting. Short-term traders face significant headwinds from the powerful downtrend and lack of near-term positive catalysts. A minimum holding period of 18-24 months is suggested to allow for operational improvement and market sentiment to potentially shift.
